納斯達克一家上市公司將在BTC中收購10億美元

又有一家納斯達克公司上市公司宣布，該公司將參加具有里程碑意義的1億美元比特幣（BTC）的獨家談判。

One More Nasdaq Listed Company Has Announced It Is Entering Exclusive Negotiations for a Landmark Acquisition of $1 Billion in Bitcoin (BTC).

又有一家納斯達克公司上市公司宣布，該公司將參加具有里程碑意義的10億美元比特幣（BTC）的獨家談判。

This step will see Basel Medical Group Ltd (Nasdaq: BMGL) diversify its treasury reserves significantly while allowing the company to maintain its primary focus on expanding its medical services across Asia. The move marks a strategic financial initiative aimed at bolstering its balance sheet and supporting its ambitious growth in high-demand healthcare markets.

此步驟將使巴塞爾醫學集團有限公司（NASDAQ：BMGL）多樣化其財政部儲備，同時允許該公司保持其主要關注的關注，以擴大在亞洲的醫療服務。此舉標誌著旨在加強資產負債表並支持其在高需求醫療保健市場的雄心勃勃的增長的戰略財務主動性。

The company is currently in advanced talks with a consortium of institutional investors and high-net-worth individuals within the cryptocurrency sector. Through an innovative share-swap arrangement, BMGL plans to acquire the $1 billion in Bitcoin. If successful, this acquisition will be one of the largest corporate balance sheet improvements in the Asia-Pacific healthcare industry.

該公司目前正在加密貨幣領域內與機構投資者和高淨值個人的財團進行高級會談。 BMGL通過創新的股票交易安排，計劃收購10億美元的比特幣。如果成功，此次收購將是亞太醫療保健行業最大的公司資產負債表改進之一。

The proposed BTC acquisition will provide multiple strategic benefits to BMGL:

擬議的BTC收購將為BMGL提供多種戰略利益：

BMGL will be positioned as a well-capitalized player in emerging Asian healthcare markets, with increased resources for expansion.

BMGL將被定位為新興亞洲醫療保健市場的資本良好的參與者，並增加了擴張資源。

This acquisition aligns with BMGL's commitment to exploring cutting-edge financial instruments and technologies.

這項收購與BMGL致力於探索最先進金融工具和技術的承諾相吻合。

The move is anticipated to generate significant interest from investors and the financial press, enhancing BMGL's visibility and brand recognition.

預計此舉將引起投資者和金融媒體的重大興趣，從而增強了BMGL的知名度和品牌認可。

The acquisition is expected to be finalized by the end of the current quarter, pending standard closing conditions and any required regulatory approvals.

預計收購將在本季度結束時完成，以待決結束條件和任何要求的監管批准。

“We are excited about the potential of this $1 billion acquisition to provide us with the unprecedented financial capacity to drive our growth strategy in Asia, all while maintaining disciplined financial management,” said Dr. Darren Chhoa, CEO of Basel Medical Group.

巴塞爾醫療集團首席執行官達倫·喬亞（Darren Chhoa）博士說：“我們為這筆10億美元收購的潛力為我們提供了前所未有的財務能力來推動我們在亞洲的增長戰略，同時維持紀律嚴明的財務管理。”

“This will strengthen our balance sheet and position us for swift execution as we capitalize on strategic opportunities to build a leading healthcare platform across the high-growth Asian markets.”

“這將加強我們的資產負債表並將我們定位為迅速執行，因為我們利用了在高增長亞洲市場上建立領先的醫療平台的戰略機會。”

The company will keep investors informed of any material developments in due course.

該公司將在適當的時候向投資者通報任何重大發展。